We manufacture clinical-grade pluripotent stem cells
The potential of cell therapies for hard-to-treat conditions has been limited by the complex and costly logistics of autologous treatments. Therapy cells are produced “from the patient, for the patient.”
Off-the-shelf, allogenic approaches – where treatments are manufactured from a healthy donor’s cells and used for multiple patients – have moved into the spotlight as a way to accelerate time-to-patient and reduce cost significantly. Boosting immune compatibility of donor cells and ensuring their fit for therapeutic purposes is critical to realize such advanced therapy medicinal products.
This is where RHEINCELL excels.
We produce GMP-grade human induced pluripotent stem cells (iPSCs) from a unique source of clinically-approved, donor-consented umbilical cord blood units. Furthermore, we expedite allogenic approaches with a collection of HLA-homozygous iPSCs that reduce transplant rejection. Partnering with innovative developers of off-the-shelf iPSC-based therapies, we advance cell therapies where they begin: at the cell.
what we do
The latest news from RHEINCELL
RheinCell’s success story
Read about the growth path of RheinCell and what the future might hold in the IHK/Chamber of Commerce and Industry-Magazin
RheinCell Therapeutics to be acquired by Catalent, Accelerating the Industrialization of iPSC-based Therapies
Catalent Pharma Solutions, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics, cell and gene therapy and consumer health products, has agreed to acquire RHEINCELL Therapeutics.
RHEINCELL IS AT ADVANCED THERAPIES 2021 VIRTUAL
Continuously seeking new partnerships and innovative collaborations, Thomas Marx is attending this year's virtual session of Advanced Therapies Congress & Expo. Cutting-edge talks and insightful discussions packed into 3 high-power days will keep Thomas busy. Make sure to join him.